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Beta-blocker choice and 
exchangeability in patients 
with heart failure and chronic 
obstructive pulmonary disease: an 
italian register-based cohort study
Maurizio Sessa  1,2, Annamaria Mascolo2, Daniel Bech Rasmussen3,4, Kristian Kragholm5, 
Magnus thorsten Jensen6, Liberata Sportiello2, Concetta Rafaniello2, Giuseppe Michele tari7, 
claudia pagliaro7, Morten Andersen  1, Francesco Rossi2 & Annalisa capuano2
clinical guidelines suggest that for patients with heart failure and concurrent chronic obstructive 
pulmonary disease (COPD), metoprolol/bisoprolol/nebivolol should be preferred over carvedilol. 
However, studies suggest a high proportion of carvedilol usage that remains unexplained. Therefore, 
we aimed to investigate the predictors of carvedilol choice in patients with heart failure and COPD 
that were naïve to carvedilol or metoprolol/bisoprolol/nebivolol. Caserta Local Health Unit databases 
(Italy) were used as data sources. Age, sex, chronic/acute comorbidities, and co-medications were 
included in a logistic regression model to assess predictors of carvedilol choice. Chronic comorbidities 
include those defined in the Elixhauser comorbidity index and all hospitalizations within two years 
prior to the first beta-blocker prescription. Comedications include all redeemed prescriptions within 
one year prior to the beta-blocker prescription. Kernel density estimations were used to assess the 
overlap in propensity and preference scores distributions for receiving carvedilol and thereby potential 
beta-blocker exchangeability. Totally, 10091 patients composed the study population; 2011 were 
exposed to carvedilol. The overlapping of propensity scores distributions was 57%. Accordingly, the 
exchangeability was not reached. Atrioventricular block (Odds Ratio, OR 8.20; 95% Confidence Interval, 
95% CI 1.30–51.80), cerebrovascular thrombosis (OR 7.06; 95% CI 1.14–43.68), chronic kidney disease 
(OR 4.32; 95% CI 1.16–16.02), and acute heart failure (OR 1.97; 95% CI 1.28–3.03) hospitalizations 
were statistically significantly associated with carvedilol choice. Analogously, human insulin (OR 
3.00; 95% CI 1.24–7.24), fondaparinux (OR 2.47; 95% CI 1.17–5.21) or strontium ranelate (OR 2.03; 
95% CI 1.06–3.90) redeemed prescriptions. In conclusion, this study suggests the absence of beta-
blockers exchangeability and a preferential choice of carvedilol in patients with heart failure, COPD 
and concurrent chronic kidney disease, atrioventricular block, cerebrovascular thrombosis, acute heart 
failure or redeeming human insulin, fondaparinux or strontium ranelate prescriptions. Therefore, 
it suggests that choice of prescribing carvedilol over metoprolol/bisoprolol/nebivolol is driven by 
differences in comorbidities and co-treatments.
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Beta-blockade is a crucial pharmacological therapy to improve survival and to reduce morbidity in patients with 
heart failure and concurrent chronic obstructive pulmonary disease1. The benefits of beta-blockade in heart fail-
ure are due to their mitigation of the negative pathological consequences associated with adrenergic nervous 
system hyperactivity that gradually occurs in a chronically failing heart2. The sympathetic overdrive in heart 
failure is associated with an increased risk of arrhythmias, progressive dysfunction of the left ventricle, and myo-
cardial insult, phenomena that have a negative impact on disease progression and prognosis3. In fact, adrenergic 
nervous system hyperactivity determines increased peroxidative and lipoperoxidative metabolism and demands 
of oxygen in the myocardium leading to the overproduction of reactive oxygen species that in turn determines 
local inflammation, apoptosis, and necrosis resulting in interstitial fibrosis and heart remodelling4,5. In Europe, 
four beta-blockers are currently indicated for heart failure, three beta-1 adrenoceptor selective, metoprolol, 
bisoprolol and nebivolol, and a non-selective, carvedilol. Metoprolol and bisoprolol are both second generation 
beta-blockers or rather they have high beta-1 adrenoceptor selectivity and they both lack intrinsic sympathom-
imetic activity. Bisoprolol has 20 times higher selectivity for the beta-1 adrenoceptor than metoprolol and it has 
a longer half-life (9–12 hours versus 3–7 hours) and bioavailability (90 versus 12%). Due to its high selectivity for 
the beta-1 adrenoceptor, bisoprolol has minimal effects on insulin sensitivity while, on the other hand, metopr-
olol has an additional membrane-stabilizing activity on the heart. Carvedilol and nebivolol are third generation 
beta-blockers with additional vasodilatation properties. Nebivolol is beta-1 adrenoceptor selective beta-blockers 
with a long half-life and bioavailability (12–96%) which, through a mechanism mediated by nitric oxide, is able to 
provide a reduction of the arteries tone that when targeted on the coronaries guarantees additional cardioprotec-
tive and anti-ischemic effects. Carvedilol is a non- beta-1 adrenoceptor selective beta-blockers with an intrinsic 
sympathomimetic activity, long half-life (7–10 hours) and additional vasodilatation properties mediated by the 
alpha-1 adrenoceptor blockade. It has anti-oxidant properties, it mitigates calcium overload by modulating ryan-
odine channels, and it ameliorates insulin sensitivity6. Despite a clinical and pharmacological rationale suggest 
the use of beta-blockers in heart failure, reluctance to prescribe beta-blockers in patients with the concurrent 
chronic obstructive pulmonary disease has been observed in multiple clinical settings. The leading factor for 
under-prescription of beta-blockers in this subpopulation is the concern of adverse respiratory effects medi-
ated by beta-blockers through beta-2 adrenoceptors in the airway. The magnitude of the bronchoconstriction is 
strongly correlated with beta-1 adrenoceptor selectivity7. For this reason, current clinical guidelines suggest that 
for patients with heart failure and concurrent chronic obstructive pulmonary disease, metoprolol, bisoprolol or 
nebivolol should be preferred8,9. However, studies suggest a high proportion of carvedilol usage that is in oppo-
sition to above-mentioned recommendations10. Several adverse clinical consequences have been associated with 
carvedilol usage in patients with heart failure and concurrent chronic obstructive pulmonary disease such as a 
reduction in the lung function11 that may lead to subclinical effects on respiratory parameters10,12,13. Additionally, 
carvedilol may lead to a higher rate of unfavourable hemodynamic alterations leading to an increased risk of 
heart failure hospitalization, on both short and long-term following treatment commencement10,12. In virtue 
of the potential negative clinical consequences associated with carvedilol choice in patients with heart failure 
and chronic obstructive pulmonary disease naïve to beta-blockers, understanding key factors that may lead to 
a preferential choice of such prescriptions is crucial and, in this regard, the evidence is scarce. Our hypothesis is 
that concurrent chronic/acute comorbidities and comedications may have driven the choice of carvedilol over 
metoprolol/bisoprolol/nebivolol and this may have led to the absence of exchangeability of these beta-blockers 
in this subpopulation. To overcome this gap in knowledge, the current study aims to investigate carvedilol and 
metoprolol/bisoprolol/nebivolol exchangeability and the predictors of carvedilol choice in patients with heart 
failure and chronic obstructive pulmonary disease that were naïve to beta-blockers. The investigated predictors 
included chronic comorbidities defined in the Elixhauser comorbidity index14, all hospitalizations and redeemed 
prescriptions within two and one years prior to the first beta-blocker prescription, respectively.
Methods
Data sources. Health data sources of the Caserta Local Health Unit were used to identify the study popula-
tion. These data sources cover approximately 1,000,000 citizens living in the catchment area of Caserta (Campania 
Region, Italy). For reimbursement purposes, the data sources store information on socio-demographic character-
istics of residents, redeemed prescriptions, inpatient and outpatient hospitalizations and hospital contacts. Data 
contained in Caserta Local Health Unit administrative databases are pseudonymized to comply with current law 
on data protection and privacy.
Study population. The study population included patients who (1) during the period December 31, 2010 
to September 30, 2017 had a hospitalization/hospital contact for heart failure, (2) redeemed their first carve-
dilol, metoprolol, bisoprolol or nebivolol prescription after this hospitalization for heart failure (at least one 
year wash-out period for the beta-blocker prior to the heart failure hospitalization), and (3) redeemed drugs for 
obstructive airway diseases (Anatomical Therapeutic Chemical Classification, ATC R03) prior to the redemption 
of the first prescription of aforementioned beta-blockers (Fig. 1). In Italy, drugs for obstructive airway disease 
(ATC R03) that are reimbursed by the Italian Healthcare system are indicated for asthma or chronic obstructive 
pulmonary disease12. However, the use of beta-blockers in asthma is relatively contraindicated in the summaries 
of product characteristics and is not recommended in current clinical guidelines. Therefore, we believe that by 
using this approach we identified mostly patients with chronic obstructive pulmonary disease.
Study outcome. The study outcome was the probability of redeeming a carvedilol as opposed to metoprolol/
bisoprolol/nebivolol prescription.
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Potential predictors for carvedilol choice. Age, gender, year of inclusion in the study population 
and chronic comorbidities according to the Elixhauser Comorbidity Index were included as potential predic-
tors14. Chronic comorbidities were identified by hospital discharge codes prior to the redemption of the first 
beta-blocker prescription. Other potential predictors included all primary diagnosis for hospital contact/hospi-
talization and redeemed prescriptions that occurred 2 and 1 year/s prior to the redemption of the first carvedilol, 
metoprolol, bisoprolol, or nebivolol prescription, respectively.
Statistical analyses. A prevalence proportion (the prevalence of the event among patients exposed to carve-
dilol divided by the prevalence of the event among patients exposed to metoprolol, bisoprolol, or nebivolol) for all 
primary diagnosis for hospital contact/hospitalization and redeemed prescriptions that occurred 2 and 1 year/s 
prior to the redemption of the first carvedilol, metoprolol, bisoprolol, or nebivolol prescription was computed and 
the 500 event most prevalent among carvedilol users were selected. This is a crucial preliminary step to identify 
the most relevant variables for propensity score assessment in highly dimensional datasets. The 500 top-ranked 
potential predictors selected with the abovementioned method were used as independent variables in a logistic 
regression model to compute the propensity score for receiving carvedilol rather than metoprolol, bisoprolol, 
and nebivolol. The predicted probability of receiving carvedilol given the set of potential predictors was used to 
assess the exchangeability between treatments groups given their covariate distributions. The null hypothesis was 
the absence of clinical or demographic differences between recipients of carvedilol versus metoprolol, bisoprolol, 
or nebivolol or rather beta-blocker exchangeability (referred to as empirical ‘equipoise’ in Greenland et al.)15. 
According to Walker and colleagues, the predicted value from the above-mentioned logistic regression was used 
to compute a preference score as following: ln {A/(1 − A)} = ln (B/(1 − B) − ln (C/(1 − C)) where A is the pref-
erence score, B is the propensity score and C is the prevalence of exposure to carvedilol16. To assess beta-blocker 
exchangeability among beta-blockers, a Kernel density estimation was used to assess the overlap in propensity 
scores areas for carvedilol and metoprolol/bisoprolol/nebivolol users. Additionally, as suggested by Walker and 
colleagues, by using a Kernel density estimation, we tested if half of the distributions of the preference score was 
between 0.3 and 0.7 between carvedilol and metoprolol/bisoprolol/nebivolol users16. Baseline characteristics of 
the two cohorts were compared using the t-tests for continuous variables and χ2 test for categorical variables.
Compliance with ethical standards. According to Italian National laws, ethical approval or informed 
consent for register-based studies is not required.
Results
The study population’s demographic and clinical characteristics are provided in Table 1. In total, 10091 patients 
were included in the study population of which 2011 (19.9%) exposed to carvedilol. The mean age was 77.7 years 
(standard deviation of 11.8 years).
Beta-blocker exchangeability in patients with heart failure and concurrent chronic obstruc-
tive pulmonary disease. The estimated overlapping area of two kernel density estimations of propensity 
scores among treated with carvedilol and metoprolol/bisoprolol/nebivolol was 57% (Fig. 2). The exchangeability 
among beta-blockers according to the preference score criteria was not reached (Fig. 3). Both results suggest 
the absence of exchangeability between treatment groups and therefore significant differences in comorbidities/
co-treatments distributions among the 500 top-ranked potential predictors between patients receiving carvedilol 
over metoprolol/bisoprolol/nebivolol.
Predictors of carvedilol choice. Odds ratios and 95% confidence intervals (95% CI) of statistically sig-
nificant predictors for carvedilol prescription over metoprolol/bisoprolol/nebivolol prescriptions are provided 
in Fig. 4. Age, gender, and comorbidities according to the Elixhauser Comorbidity Index were not predictors of 
carvedilol choice. Among the 500 top-ranked potential predictors, atrioventricular block (OR 8.20; 95% CI 1.30–
51.80), cerebrovascular thrombosis (OR 7.06; 95% CI 1.14–43.68), chronic kidney disease (OR 4.32; 95% CI 1.16–
16.02), and acute heart failure (OR 1.97; 95% CI 1.28–3.03) hospitalizations/hospital contacts within two years 
prior to the first beta-blocker prescription were associated with carvedilol choice. Analogously, patients redeem-
ing a prescription of human insulin, fondaparinux or strontium ranelate within one year prior to the beta-blocker 
prescription had significantly higher odds of receiving carvedilol over metoprolol/bisoprolol/nebivolol.
Figure 1. Example of the temporal sequence of events needed for patients to be included in the study 
population.
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Discussion
This study suggests that among patients with heart failure and chronic obstructive pulmonary disease, the choice 
of prescribing carvedilol over metoprolol/bisoprolol/nebivolol is driven by differences in comorbidities and 
co-treatments. Predictors of carvedilol choice were chronic comorbidities and co-treatments including chronic 
kidney disease, human insulin, fondaparinux, strontium ranelate or recent acute episode of acute heart failure, 
cerebrovascular thrombosis or atrioventricular block.
Variable
Metoprolol/Bisoprolol/




(n = 10091) p-value
Age 77.8 (11.7) 77.7 (11.9) 77.8 (11.8) 0.922
Sex (male) 4092 (50.7) 970 (48.2) 5062 (50.2) 0.079
Pulmonary embolism 77 (1.0) 16 (0.8) 93 (0.9) 0.595
Peripheral arterial disease 385 (4.8) 88 (4.4) 473 (4.7) 0.496
Liver disorders 400 (5.0) 88 (4.4) 488 (4.8) 0.309
Cancer 1248 (15.4) 306 (15.2) 1554 (15.4) 0.825
Chronic kidney disease 526 (6.5) 123 (6.1) 649 (6.4) 0.553
Arterial embolism 1640 (20.3) 373 (18.5) 2013 (19.9) 0.084
Diabetes mellitus type 2 1698 (21.0) 420 (20.9) 2118 (21.0) 0.922
Hypertension 2766 (34.2) 679 (33.8) 3445 (34.1) 0.711
Acute myocardial infarction 1214 (15.0) 290 (14.4) 1504 (14.9) 0.518
Atrial fibrillation 343 (4.2) 88 (4.4) 431 (4.3) 0.842
Ventricular fibrillation 423 (5.2) 104 (5.2) 527 (5.2) 0.953
Valvular Disease 291 (3.6) 70 (3.5) 361 (3.6) 0.846
Pulmonary Circulation 
Disorders 94 (1.2) 23 (1.1) 117 (1.2) 1.000
Depression 56 (0.7) 17 (0.8) 73 (0.7) 0.565
Alcohol Abuse 46 (0.6) 3 (0.1) 49 (0.5) 0.024
Obesity 240 (3.0) 85 (4.2) 325 (3.2) 0.005
Coagulopathy 30 (0.4) 6 (0.3) 36 (0.4) 0.778
Rheumatoid Arthritis 24 (0.3) 10 (0.5) 34 (0.3) 0.241
Solid Tumour without 
Metastasis 64 (0.8) 18 (0.9) 82 (0.8) 0.747
Lymphoma 15 (0.2) 4 (0.2) 19 (0.2) 1.000
Table 1. Demographic and clinical characteristics of patients with heart failure and chronic obstructive 
pulmonary disease that received for the first time a prescription of carvedilol, metoprolol, bisoprolol or 
nebivolol and that were resident in the catchment area of Caserta Local Health Unit (Campania Region, Italy).
Figure 2. Kernel density estimations of propensity score among patients treated with carvedilol and 
metoprolol/bisoprolol/nebivolol having heart failure and chronic obstructive pulmonary disease located in the 
catchment area of Caserta Local Health Unit (Campania Region, Italy).
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European clinical guidelines on chronic heart failure released during the study period do not state any prefer-
ence among beta-blockers in the aforementioned clinical conditions and they do not provide recommendations 
in the clinical setting of multiple comorbidities. However, clinical evidence seems to support the choice of carve-
dilol over other beta-blockers in the clinical scenario listed above.
Carvedilol was found beneficial for patients with chronic kidney disease due to its ability to reduce cardiac 
output and renin release, as to its ability to reduce renovascular constriction through its alfa-1 and beta-1 receptor 
antagonism. Additional, carvedilol was useful due to its enhanced renovascular dilation through beta2-receptor 
antagonism17. These effects, along with to the ability of all beta-blockers in reducing sympathetic over-activity, 
were found associated with attenuation in the increase of albuminuria and hyperkalaemia, but also to an absence 
of an increase in serum creatinine, events typically observed in patients with chronic kidney disease. In addition, 
the aforementioned effects were found associated with high effectiveness in protecting from cardiovascular events 
in patients with chronic kidney disease17–19.
With regards to diabetes mellitus and in particular human insulin as a predictor for carvedilol choice, evidence 
suggests a favourable effect of carvedilol on glycaemic control in diabetic patients when compared to metoprolol. 
In particular, in the Glycaemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensive 
(GEMINI) trial, patients treated with carvedilol had a lower probability of new onset diabetes mellitus, microal-
buminuria (a surrogate marker for endothelial function) and an increased insulin sensitivity compared to patients 
treated with metoprolol. Additionally, a recent systematic review suggested even more beneficial effect of carve-
dilol in diabetes mellitus, including a reduced risk of new onset of atherogenic dyslipidaemia or weight gain 
among treated with carvedilol20,21.
Regarding the role of strontium ranelate as a predictor for carvedilol choice, it should be mentioned that 
our study population had a mean age of 77.8 years with a proportion of women of 49.8% and, therefore, at high 
risk of osteoporosis. Additionally, patients with chronic obstructive pulmonary disease have an increased risk of 
all-cause and site-specific fractures22. In Italy, during the study period, strontium ranelate was indicated for “the 
treatment of severe osteoporosis in postmenopausal women and in adult men at high risk of fracture”. Observational 
studies suggest an association between beta-blocker treatments, and in particular carvedilol, and reduced risk of 
bone fracture and an inherent protective effect of this drug class. On the other hand, pooled data from clinical 
Figure 3. Kernel density estimations of preference score among patients treated with carvedilol and 
metoprolol/bisoprolol/nebivolol having heart failure and chronic obstructive pulmonary disease located in the 
catchment area of Caserta Local Health Unit (Campania Region, Italy).
Figure 4. Predictors of carvedilol prescription over metoprolol/bisoprolol/nebivolol for patients with heart 
failure and chronic obstructive pulmonary disease located in the catchment area of Caserta Local Health Unit 
(Campania Region, Italy).
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trials that investigate the effect of carvedilol on congestive heart failure do not seem to support this hypothesis23,24. 
Mechanistic studies performed in pre-clinical models support the hypothetic involvement of β-adrenoceptor in 
the aforementioned phenomena by showing that beta-blocker treatment improves bone density and mass while 
β-adrenoceptor agonists led to the opposite effect. In particular, the effect seems mediated by the β2-adrenoceptor 
on osteoblasts and the sympathetic nervous system25. It should be mentioned that no formal potential drug-drug 
interactions were found between strontium ranelate and carvedilol or metoprolol/bisoprolol/nebivolol by using 
Micromedex®26. Therefore we excluded potential drug-drug interaction as a plausible explanation for carvedilol 
choice in these patients.
In relation to fondaparinux as a predictor of carvedilol prescription, we need to mention that during the study 
period, fondaparinux was indicated for the prevention of venous thromboembolism in multiple clinical scenarios. 
We believe that a plausible explanation for the higher proportion of fondaparinux use in patients treated with 
carvedilol may be due to the fear of potential drug-drug interactions. In particular, clinical guidelines advocate 
the use of fondaparinux for venous thromboembolism prophylaxis in patients with a history of heparin-induced 
thrombocytopenia27. Alternatives to fondaparinux in the aforementioned clinical scenario are the direct acting 
oral anticoagulants27. However, while carvedilol has no potential drug-drug interactions with fondaparinux26, it 
has with direct acting oral anticoagulants, and in particular dabigatran and edoxaban. Given carvedilol’s ability to 
inhibit the glycoprotein-P, it may induce an increased plasma concentration of the aforementioned direct acting 
oral anticoagulants with a consequent increased risk of bleeding26. Therefore, we speculate that the occurrence of 
these clinical scenarios may have led the choice of carvedilol in patients exposed to fondaparinux.
In relation to acute heart failure, previous studies have found different effects on the cardiovascular system 
among beta-blockers with different β-1 adrenoceptor selectivity in patients that experienced acute heart failure 
and that were exposed to inotropic agents (i.e. dobutamine). In this subpopulation, metoprolol did not modify 
the cardiac index, heart rate, and systemic vascular resistance providing only a modest effect on the pulmonary 
artery and systemic arterial pressures within the first 12 months of treatment. In contrast, substantial differences 
were observed for carvedilol. The aforementioned effects were attributed to the blockade of β-2-receptors in the 
vascular system and to the other pharmacological properties of carvedilol28,29.
It should be mentioned that clinical evidence exists on the beneficial effect of beta-blockers on the risk of early 
death in patients with ischemic stroke30. In pre-clinical and in-vitro models, authors found neuroprotective effects 
of beta-blockers with additional vasodilatation properties, like carvedilol and nebivolol. Notably, for carvedilol, a 
study suggests that these effects may be mediated also by the β2 adrenal receptors antagonism and cyclooxygenase 
2 isozyme/prostacyclin pathways31,32. Additionally, clinical evidence seems to support the hypothesis of a reduced 
risk of mortality due to stroke in patients exposed to carvedilol versus those exposed to metoprolol33.
Regarding the choice of carvedilol in patients with a recent episode of atrioventricular block, it should be 
highlighted that clinically relevant differences were observed among beta-blockers indicated for heart failure on 
the heart rate. In particular, among aforementioned beta-blockers, carvedilol provided a weaker effect on heart 
rate at rest when compared to other beta-blockers especially in patients with a low sympathetic tone which may 
be beneficial in patients with a recent episode of atrioventricular block. It was hypothesized that this effect might 
be caused by the increased sympathetic drive consequent to the peripheral vasodilation resulting from the acces-
sories vasodilatation properties of carvedilol34,35.
Strengths and limitations. A major limitation of this study is the lack of information on the indication 
of use for redeemed prescriptions. For drugs having ATC code R03, it may have led to a misclassification of the 
exposure. In fact, these drugs are mainly indicated for both asthma and chronic obstructive pulmonary diseases. 
Therefore, we may have classified patients with asthma as having chronic obstructive pulmonary disease. We 
believe that the magnitude of this type of misclassification is very low because Caserta Local Health unit data-
bases contain information on drugs reimbursed by the national health system, and most of the reimbursed drugs 
in this ATC group are indicated for chronic obstructive pulmonary disease as shown elsewhere36. Additionally, 
beta-blockers are relatively contraindicated in asthma.
The second major limitation of this study is the lack of information on over-the-counter drugs/drugs not 
requiring a medical prescription. In particular, we may have not detected predictors for carvedilol choice among 
acute comorbidities. In the Italian healthcare system, over-the-counter drugs/drugs not requiring a medical pre-
scription are generally not indicated for chronic and/or invalidating diseases with a high burden for the patient 
and they are usually used as symptomatic treatments37. Another limitation of this study is the potential misclas-
sification of chronic comorbidities identified through hospitalizations/hospital contacts. In fact, we lack infor-
mation for those patients hospitalized and/or with a hospital contact outside the catchment area of Caserta local 
health unit. However, we believe that the magnitude of this bias is low because these patients will receive in most 
of the cases a pharmacological treatment that is tracked in Caserta Local health unit databases.
The third major limitation of this study is the lack of information on the ethnicity/race of the study popula-
tion for which, recent studies found an association with a differential response to beta-blockers treatment38,39. 
However, we believe that this limitation may have introduced a negligible bias. In fact, during the study period, 
the number of immigrants in the catchment area of Caserta was between 3000–4000, or rather 0.3–0.4% of the 
study population and, mostly with an age lower than 60 years and, therefore, with a lower probability of having 
heart failure40.
Regarding the lack of information on the cytochrome P450 2D6 polymorphisms in the study population, 
despite carvedilol is extensively metabolized by this enzyme41,42, to date, in Europe, none of the summaries of 
product characteristics of medicinal products containing carvedilol include polymorphisms of the gene codify-
ing this enzyme as a “contraindications”/“special warnings and precautions for use” for its prescription. Therefore, 
we believe that even in the setting of poor, rapid or ultra-rapid metabolizers, it should not have influenced the 
prescription choice.
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Finally, as for all observational studies, we cannot exclude the presence of unmeasured confounders that may 
have introduced biases in our analysis. Strengths include the use of the entire population of patients enlisted in 
Caserta local health unit databases reducing the risk of selection bias and the possibility of providing results based 
on real-world data from routine clinical practice.
conclusion
In conclusion, this study showed that no beta-blocker exchangeability was found among carvedilol and meto-
prolol/bisoprolol/nebivolol in patients with heart failure and chronic obstructive pulmonary disease. In this 
subpopulation, concurrent chronic (i.e. chronic kidney disease) and acute comorbidities (i.e. acute heart fail-
ure, cerebrovascular thrombosis or atrioventricular block) or concurrent pharmacological treatments (i.e. 
fondaparinux, human insulin and strontium ranelate) may drive the choice of prescribing carvedilol over 
metoprolol/bisoprolol/nebivolol.
Data Availability
The datasets generated during and/or analyzed during the current study are not publicly available due to legal 
reservations but are available from the corresponding author on reasonable request.
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